SCHEMBL9607500

SCHEMBL9607500

Cc1cc(-c2cnc3sc(N)nc3c2)cc2c1OCCN(c1cc(N)nc(N)n1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
PIK3CA P42336 4/20 0.31
MTOR P42345 4/20 0.31
PIK3R1 P27986 2/20 0.31
NUDT1 P36639 1/20 0.31
PIK3CD O00329 2/20 0.30
PIK3CB P42338 2/20 0.30
PIK3CG P48736 2/20 0.30
SYK P43405 1/20 0.30
MAP3K9 P80192 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16476866 0.93 CRHBP (0.42) HRH4HRH3CRHBPCRHR2PIK3CA
SCHEMBL16476845 0.91 CYP1A2 (0.40) CRHBPCRHR2PIK3CAMTORPIK3R1
SCHEMBL16476863 0.91 PIK3R1 (0.30) PIK3CAMTORPIK3R1
SCHEMBL16459945 0.86 PIK3CA (0.33) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL16476919 0.86 PIK3CA (0.32) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL16476865 0.86 PIK3CA (0.34) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL16476857 0.85 PIK3CA (0.33) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL16460297 0.85 GRIN2D (0.39) PIK3CAMTORPIK3R1GRIN2DGRIN3B
SCHEMBL16476856 0.84 PIK3CA (0.31) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL16476910 0.84 CHEK1 (0.35) PIK3CAMTORPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
WO-2012071519-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA HRH4 698/4885HRH3 806/4885CRHBP 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.